These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 27709364)
1. β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. Coelho M; Soares-Silva C; Brandão D; Marino F; Cosentino M; Ribeiro L J Cancer Res Clin Oncol; 2017 Feb; 143(2):275-291. PubMed ID: 27709364 [TBL] [Abstract][Full Text] [Related]
2. Antiproliferative effects of β-blockers on human colorectal cancer cells. Coelho M; Moz M; Correia G; Teixeira A; Medeiros R; Ribeiro L Oncol Rep; 2015 May; 33(5):2513-20. PubMed ID: 25812650 [TBL] [Abstract][Full Text] [Related]
3. β-Adrenoceptors in Cancer: Old Players and New Perspectives. Amato R; Lucchesi M; Marracci S; Filippi L; Dal Monte M Handb Exp Pharmacol; 2024; 285():665-688. PubMed ID: 37982890 [TBL] [Abstract][Full Text] [Related]
4. The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. He RH; He YJ; Tang YJ; Zhou HH; McLeod HL; Liu J Pharmacogenomics; 2016; 17(1):74-9. PubMed ID: 26652861 [TBL] [Abstract][Full Text] [Related]
5. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of P38/MAPK pathway. Huang XY; Wang HC; Yuan Z; Huang J; Zheng Q Hepatogastroenterology; 2012 May; 59(115):889-93. PubMed ID: 22020907 [TBL] [Abstract][Full Text] [Related]
6. β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. Nilsson MB; Le X; Heymach JV J Neuroimmune Pharmacol; 2020 Mar; 15(1):27-36. PubMed ID: 31828732 [TBL] [Abstract][Full Text] [Related]
7. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Tang J; Li Z; Lu L; Cho CH Semin Cancer Biol; 2013 Dec; 23(6 Pt B):533-42. PubMed ID: 24012659 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic implications of beta-adrenergic receptor pharmacodynamic properties. Taira CA; Carranza A; Mayer M; Di Verniero C; Opezzo JA; Höcht C Curr Clin Pharmacol; 2008 Sep; 3(3):174-84. PubMed ID: 18781904 [TBL] [Abstract][Full Text] [Related]
9. Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Montoya A; Amaya CN; Belmont A; Diab N; Trevino R; Villanueva G; Rains S; Sanchez LA; Badri N; Otoukesh S; Khammanivong A; Liss D; Baca ST; Aguilera RJ; Dickerson EB; Torabi A; Dwivedi AK; Abbas A; Chambers K; Bryan BA; Nahleh Z Oncotarget; 2017 Jan; 8(4):6446-6460. PubMed ID: 28031536 [TBL] [Abstract][Full Text] [Related]
10. Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation. Gerhardt CC; Gros J; Strosberg AD; Issad T Mol Pharmacol; 1999 Feb; 55(2):255-62. PubMed ID: 9927616 [TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: beta-adrenergic signaling in cancer. Cole SW; Sood AK Clin Cancer Res; 2012 Mar; 18(5):1201-6. PubMed ID: 22186256 [TBL] [Abstract][Full Text] [Related]
12. The role of β-adrenergic receptors in the cardioprotective effects of beta-preconditioning (βPC). Salie R; Moolman JA; Lochner A Cardiovasc Drugs Ther; 2011 Feb; 25(1):31-46. PubMed ID: 21225332 [TBL] [Abstract][Full Text] [Related]